diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
index b3b8df3d3..2c3b94353 100644
--- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
+++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
@@ -147,3 +147,10 @@ Omada Health's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months (
 **Source:** Truveta Research ISPOR 2025
 
 Truveta confirms indication-specific persistence gap: T2D indication shows 64.8% annual discontinuation versus 46.5% for obesity-only, reinforcing that diabetes patients maintain therapy at higher rates than obesity-only patients.
+
+
+## Supporting Evidence
+
+**Source:** JAMA Network Open 2025 (PMC11786232)
+
+JAMA Network Open 2025 study confirms the obesity vs. T2D adherence stratification with one-year data: 64.8% of obesity-only patients discontinued within one year vs. 46.5% of T2D patients. This provides peer-reviewed confirmation of the adherence differential at the one-year mark, supporting the two-year 15% persistence finding with earlier-stage data from a different population cohort.
diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
index 9987dde41..d967d4a91 100644
--- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
+++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
@@ -81,3 +81,10 @@ Topics:
 **Source:** Truveta Research ISPOR 2025
 
 Truveta ISPOR 2025 data confirms income >$80,000 predicts lower discontinuation rates even among commercially insured patients, demonstrating that financial access affects adherence independent of insurance coverage status. The income effect persists after controlling for comorbidities, age, and provider type.
+
+
+## Supporting Evidence
+
+**Source:** JAMA Network Open 2025 (PMC11786232)
+
+Income >$80K predicts lower discontinuation rates in this JAMA study, providing direct evidence that financial access barriers affect not just initiation but persistence. The income gradient operates throughout the treatment lifecycle, not just at the prescription decision point.
diff --git a/inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md b/inbox/archive/health/2025-glp1-discontinuation-reinitiation-jama-open.md
similarity index 97%
rename from inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md
rename to inbox/archive/health/2025-glp1-discontinuation-reinitiation-jama-open.md
index 0ec3abcd7..af9f8d811 100644
--- a/inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md
+++ b/inbox/archive/health/2025-glp1-discontinuation-reinitiation-jama-open.md
@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: high
 tags: [glp-1, discontinuation, adherence, obesity, T2D, real-world, JAMA, persistence, weight-regain, reinitiation]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content